J&J | Zinsaufwendungen Für Schuld



Interest Expense On Debt Veränderung Datum
AbbVie USD 610M 19M 2024-12
Abbott USD 45M 6M 2024-12
Amgen USD 747M 29M 2024-12
AstraZeneca 429M 28M 2024-12
Baxter International USD 100M 1000K 2024-12
Bayer 703M 61M 2024-12
Becton, Dickinson and Co. USD 155M 0 2024-12
Biogen USD 60M 200K 2024-12
Boston Scientific USD 80M 1000K 2024-12
Bristol-Myers Squibb USD 496M 9M 2024-12
CONMED USD 8.86M 395K 2024-12
Cooper Companies USD 26M 1000K 2025-01
Dexcom USD 4.9M 200K 2024-12
Edwards Lifesciences 15.5M 1000K 2024-06
Eli Lilly USD 224.7M 78.4M 2024-12
Gilead Sciences USD 248M 10M 2024-12
GlaxoSmithKline 173M 17M 2024-12
Globus Medical 775K 1.56M 2024-09
Hologic USD 30.5M 1.5M 2024-12
Indivior 9M 1000K 2024-09
Insulet USD -1600000 6.8M 2024-12
Integra LifeSciences USD 18.98M 389K 2024-12
J&J USD 137M 56M 2024-12
Medtronic USD 179M 30M 2025-01
Merck USD 328M 2M 2024-12
Merit Medical Systems USD 7.99M 492K 2024-12
Novartis USD 275M 11M 2024-12
Pfizer USD 739M 45M 2024-12
Regeneron Pharmaceuticals USD 10.5M 3.3M 2024-12
Roche Holding CHF 311.5M 1000K 2024-12
Sanofi 62M 17M 2024-12
Stryker 42M 11M 2024-09
Tandem Diabetes Care USD 1.86M 5K 2024-12
Teva Pharmaceutical Industries USD 224M 1000K 2024-12
Vertex Pharmaceuticals USD 2.8M 4.7M 2024-12
Zimmer Biomet Holdings USD 61.9M 7.6M 2024-12
Zoetis USD 51M 6M 2024-12



J&J Zinsaufwendungen Für Schuld - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Mar 2025.